久久偷拍精品视频,成在人线av无码免费高,久久99亚洲精品久久久久,日本亂論免費影院,欧美一区二区视频97色伦,久久久久综合色一本,99热最新网址导航,国产一区二区欧美精品,久久婷婷5月综合色啪,国产精品久久精品

August 06,2024

Enitiate Bio has achieved its primary endpoint in the Phase II clinical trial of QY201 Tablets, a Class 1 innovative drug independently developed by Enitiate Bio, for the treatment of moderate-to-severe atopic dermatitis, with statistically significant and clinically meaningful results, as well as favorable safety and tolerability.

More

August 29,2023

QY201, an orally administered tablet, is a new generation JAK1/TYK2 inhibitor independently developed by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "EnitiateBio") has entered the phase II clinical trial.

More

August 18,2023

On July 26, 2023, Beijing time, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (hereinafter referred to as "EnitiateBio" or "Qiyuan") received the IND approval for QY201 from the FDA. This is the first clinical approval obtained by EnitiateBio from the FDA and the first U.S. IND application that was fulfilled by EnitiateBio on its own, marking the official launch of the overseas expansion plan of EnitiateBio QY201.

More

June 07,2023

On June 2, the inaugural meeting of thePharma-Derma-Alliance (PhDA) and the first Dermatology New Drug Clinical Research Summit Forum were held in Beijing; the alliance aims to strengthen synergistic innovation and scientific innovation in dermatology clinical research, new drug development and results transformation, and promote the linkage of "government, industry, academia, research and medicine", so as to promote the high-quality development and globalization of the dermatology innovative drug industry. The Alliance aims to promote the development and globalization of the dermatology innovative drug industry to benefit dermatology patients in China and around the world.

More

May 12,2023

On October 30, 2022, the company's Chairman and Chief Scientist, Dr. Wang Shen, Chief Executive Officer, Mr.Kevin Ding, and Chief Medical Officer, Mr. Jun Shi , were interviewed by Zhejiang Jing TV's "Creators World" to exchange and share their experiences around the company's development, the prospect of the pharmaceutical industry, and innovation and entrepreneurship.

More